An Open-Label Discontinuation Trial of Long-Term, Off-Label Antipsychotic Medication in People With Intellectual Disability: Determinants of Success and Failure

Gerda M. de Kuijper, Pieter J. Hoekstra

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)
247 Downloads (Pure)

Abstract

Although physicians are aware of the risks of prescribing long-term off-label antipsychotics in people with intellectual disability, attempts to discontinue often fail. This study aimed to identify potential determinants of successful and failed discontinuation. Long-term off-label antipsychotics were tapered in 14 weeks, with 12.5% of baseline dose every 2 weeks. Participants living in facilities offered by intellectual disability service providers, >= 6 years, with an IQ

Original languageEnglish
Pages (from-to)1418-1426
Number of pages9
JournalThe Journal of Clinical Pharmacology
Volume58
Issue number11
DOIs
Publication statusPublished - Nov-2018

Keywords

  • antipsychotic drugs
  • determinants
  • discontinuation
  • intellectual disability
  • mental health
  • off-label use
  • psychopharmacology
  • ABERRANT BEHAVIOR CHECKLIST
  • LIFE EVENTS
  • ADULTS
  • SYMPTOMS
  • DEPRESSION
  • PREVALENCE

Cite this